Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial. In this retrospective analysis, plasma samples from patients receiving capecitabine, oxaliplatin, and bevacizumab were analyzed to investigate biomarke...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Liu, Yingmiao, Starr, Mark D, Bulusu, Anuradha, Pang, Herbert, Wong, Nan Soon, Honeycutt, Wanda, Amara, Anthony, Hurwitz, Herbert I, Nixon, Andrew B
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2013
Teme:
Clinical Cancer Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3639662/
https://ncbi.nlm.nih.gov/pubmed/23634291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.71
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki